ASH 2022 | Ponatinib and blinatumomab in newly diagnosed Ph+ ALL: subgroup analysis from Phase II study
Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents results from a Phase II study (NCT03263572) assessing ponatinib and blinatumomab for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This treatment was well-tolerated, and the study reported high complete molecular response (CMR), event-free survival (EFS), and overall survival (OS) rates with ponatinib and blinatumomab combination therapy. Dr Jabbour highlights that this is a safe and effective chemotherapy-free regimen that could become the new standard of care for patients with Ph+ ALL. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Other: Advisory Role, Research Funding; Genentech: Other: Advisory Role, Research Funding; Adaptive Biotechnologies: Other: Advisory Role, Research Funding; Spectrum: Research Funding; Pfizer: Other: Advisory Role, Research Funding; Bristol Myers Squibb: Other: Advisory Role, Research Funding; Amgen: Other: Advisory Role, Research Funding; AbbVie: Other: Advisory Role, Research Funding.
